Bioscan Research Profile
Key Indicators
- Authorised Capital ₹ 3.40 M
- Paid Up Capital ₹ 2.50 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
- Revenue Growth 145.43%
- Profit Growth 163.10%
- Ebitda 220.76%
- Net Worth 43.15%
- Total Assets 13.03%
About Bioscan Research
Bioscan Research Private Limited (BRPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 13 September 2017 (Seven years and four months 28 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.40 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.00 Cr.
Anupam Lavania and Shilpa Malik serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74999GJ2017PTC099067
-
Company No.
099067
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Sep 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Bioscan Research?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shilpa Malik
|
Director | 13-Sep-2017 | Current |
|
Anupam Lavania
|
Director | 13-Sep-2017 | Current |
Financial Performance of Bioscan Research.
Bioscan Research Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 145.43% increase. The company also saw a substantial improvement in profitability, with a 163.1% increase in profit. The company's net worth Soared by an impressive increase of 43.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioscan Research?
In 2023, Bioscan Research had a public holding of 12.90%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Uma Innovations LlpAnupam Lavania and Shilpa Malik are mutual person
Charges (Loans)
₹10.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Sep 2024 | State Bank Of India | ₹1.00 Cr | Open |
How Many Employees Work at Bioscan Research?
Unlock and access historical data on people associated with Bioscan Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioscan Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioscan Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.